← 홈

Antibody

1,830개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,830개
AntibodyAbbVieApproved

adalimumab (Humira, Adalimumab treatment arm)

Psoriasis; Cardiovascular Diseases · Psoriasis

#Psoriasis#Antibody#Approved#인기#항체+5
효능 ORR 2%임상시험 56상태 ACTIVE
AntibodyIndapta Therapeutics, INC.Phase 3

Isatuximab (Isatuximab)

NHL; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#인기#항체+5
효능 ORR 67%임상시험 56상태 RECRUITING
AntibodyAstraZenecavedotin combined with pembr…Phase 3

durvalumab (Imfinzi, MEDI4736, MEDI4736 (Durvalumab) + Tremelimumab)

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Malignancies

#AdvancedSolidMalignancies#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 56상태 RECRUITING
AntibodyJanssenApproved

Guselkumab (Guselkumab)

Psoriasis; Atopic Dermatitis · Skin Inflammation

#SkinInflammation#Antibody#Approved#인기#항체+5
임상시험 55상태 RECRUITING
AntibodyBristol Myers SquibbPhase 3

nivolumab (Opdivo, Nivolumab/Relatlimab)

Cancer · Melanoma

#Melanoma#Antibody#Phase3#인기#항체+4
효능 ORR 92.9%임상시험 55상태 RECRUITING
AntibodyTracon Pharmaceuticals Inc.Phase 2

Androgen receptor inhibitor (Androgen receptor inhibitor)

Prostate Cancer · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+4
임상시험 54상태 RECRUITING
AntibodyPfizerApproved

Elranatamab (Elranatamab)

Multiple Myeloma · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 61%임상시험 54상태 RECRUITING
AntibodyGSKvedotin) against targets ex…Approved

Mepolizumab (Mepolizumab)

Chronic Rhinosinusitis With Nasal Polyps; Asthma; Eosinophilic · Asthma

#Asthma#Antibody#Approved#인기#항체+5
효능 ORR 90.3%임상시험 54상태 ACTIVE
AntibodyRocheVedotin on Brain Metastases…Phase 2

atezolizumab (Tecentriq, Atezolizumab - 28 Day Cycle)

Endometrial Cancer · Endometrial Cancer

#EndometrialCancer#Antibody#Phase2#인기#항체+5
효능 ORR 90%임상시험 53상태 RECRUITING
AntibodyAstraZenecaPreclinical

Benralizumab (Benralizumab)

Asthma · Asthma

#Asthma#Antibody#Preclinical#인기#항체+4
임상시험 53상태 ACTIVE
AntibodyEli Lilly and CompanyApproved

Ixekizumab (Ixekizumab)

Psoriasis; Atopic Dermatitis · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Approved#인기#항체+5
임상시험 53상태 RECRUITING
AntibodyRochePreclinical

Bevacizumab + Erlotinib (Bevacizumab + Erlotinib)

Solid Tumor; Advanced Solid Tumor · Solid Tumor

#SolidTumor#Antibody#Preclinical#인기#항체+4
효능 ORR 72%임상시험 52상태 RECRUITING
Antibody3D Medicines (Sichuan) Co., Ltd.Phase 2

Envafolimab (Envafolimab)

Prostate Cancer; CDK12 Gene Mutation · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
임상시험 52상태 RECRUITING
AntibodyAmgenPhase 2

Evolocumab (Evolocumab)

Atherosclerotic Cardiovascular Disease; Symptomatic Atherosclerosis · Primary Hyperlipidemia and Mixed Dyslipi

#PrimaryHyperlipidemiaandMixedDys#Antibody#Phase2#인기#항체+5
효능 ORR 33.3%임상시험 52상태 ACTIVE
AntibodyJanssenderuxtecan, datopotamab der…Phase 3

Amivantamab (Amivantamab)

Carcinoma, Non-Small-Cell Lung · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#인기#항체+5
효능 ORR 4.3%임상시험 51상태 RECRUITING
AntibodySeagenvedotin-containing regimen …Phase 2

Brentuximab (Brentuximab)

Diffuse Large B Cell Lymphoma; Mediastinal Large B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#인기#항체+5
효능 ORR 89.5%임상시험 51상태 DISCONTINUED
AntibodyRegeneronPhase 2

Cemiplimab REGN2810 (Cemiplimab REGN2810)

Plasma Cell Myeloma · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
효능 ORR 55.6%임상시험 51상태 ACTIVE
AntibodyPfizerPhase 2

PF-06863135 (Elranatamab, Elranatamab (PF-06863135))

Multiple Myeloma · FRα

#FR#Antibody#Phase2#인기#항체+5
효능 ORR 61%임상시험 51상태 ACTIVE
AntibodyNYU Langone HealthPhase 2

belimumab (belimumab)

Rheumatic Disease · Systemic Lupus Erythematosus (SLE)

#SystemicLupusErythematosusSLE#Antibody#Phase2#인기#항체+5
효능 ORR 48.4%임상시험 51상태 RECRUITING
AntibodyGenmabPhase 2

Epcoritamab (Epcoritamab)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#Antibody#Phase2#인기#항체+5
효능 ORR 0%임상시험 50상태 RECRUITING

6 / 92 페이지

← 이전다음 →